To effectively manage increased patient volumes and financial demands, healthcare organizations are adopting solutions for electronic patient records and systems that allow them to share patient information in real-time. This segment of e-health is growing, and the growth is expected to accelerate in the coming years. Ortivus is well-positioned to capitalize on this development.
Ortivus shares have been listed on the NASDAQ Stockholm Small Cap-lista since January 2, 1997.
| Stock Symbol | ISIN | Shares Outstanding | Votes/share | Total Number of Votes | |
|---|---|---|---|---|---|
| Class A | ORTI A | SE0000188930 | 1,662,682 | 10 | 16,626,820 |
| Class B | ORTI B | SE0000123085 | 42,644,786 | 1 | 42,644,786 |
The share capital is SEK 15,507,614. Share capital is divided between class A and class B shares. The number of shares outstanding is 44,307,468 of which class A amount to 1,662,682 and class B to 42,644,786. Every class A share carries 10 votes and every class B share carries one vote.
Ortivus A
Ortivus B
Hover the mouse over the graphs to see the share price at the corresponding date.
Top 10 Shareholders as per 31th of December 2020
| Number of shares | Share of Capital | ||
|---|---|---|---|
| PONDERUS INVEST AB | Series A Series B Total | 13 177 10 360 762 10 373 939 | 23.3% |
| NORDNET PENSIONSFÖRSÄKRING A | Series A Series B Total | 38 593 4 003 731 4 042 324 | 9.1% |
| FÖRSÄKRINGS AB AVANZA | Series A Series B Total | 50 287 3 694 710 3 744 997 | 8.5% |
| PETTERSSON, RUNE | Series B | 2 802 620 | 6.3% |
| FRAIM, ING-MARIE | Series B | 1 974 087 | 4.5% |
| RASPART FÖRVALTNING AB | Series B | 1 850 000 | 4.2% |
| ADOLFSSON, PER-OLA | Series B | 1 597 963 | 3.6% |
| SELIGSON & CO PHOENIX FUND | Series B | 1 574 795 | 3.6% |
| ERIKSSON, NILS-ARNE | Series B | 1 550 625 | 3.5% |
| GAGAB AB | Series B | 769 025 | 1.7% |
| Sum of top 10 shareholders | 68.3% |
- Protokoll Ortivus årsstämma 2020
- Ortivus – nya ersättningsriktlinjer till ledande befattningshavare
- 50009-043 KALLELSE till årsstämma i Ortivus AB
- Revisorsyttrande
- Ortivus Valberedningens arbete 2020
- 50009-047 Ortivus-styrelsen-redovisning-av-resultatet-av-ersättningskommitten 2020
- 50009-043 instruktion valberedning
- fullmaktsblankett årsstämma 2020
23-12-2020
Ortivus AB and OsatuS. Coop / Bexencardio have decided on a collaboration through an exclusive
Read more
22-12-2020
As previously announced, Ortivus was on December 10, awarded a contract for the delivery of
Read more
10-12-2020
Ortivus has been awarded a contract for the delivery of equipment to Region Jönköping's ambulance
Read more
21-08-2020
Ortivus has successfully completed large deliveries to our British customers during the quarter
Read more
06-07-2020
Ortivus AB and SCHILLER AG have decided on a collaboration through a distributor agreement for
Read more
The board of Ortivus AB (publ) has decided to carry out a 100% secured rights issue of approximately SEK 9 million. The Board’s decision is conditional on the approval of the forthcoming Extraordinary General Meeting, which will be held on February 18, 2019. The proposed pre-emptive share issue intends to improve the Company’s financial position while allowing for continued development of the Company’s operations.
(Documents below are in Swedish only)
The Board of Directors of Ortivus AB (publ) has, on the basis of authorization from the Annual General Meeting 2019, decided on a new issue comprising 7,500,000 new B shares directed at a small number of specially selected investors. The total share issue raises SEK 15 million before costs for issuing of new shares. The new shares are issued at a subscription price corresponding to SEK 2 per share. The subscription price has been determined on a market basis and corresponds to the volume-weighted price of the company’s B shares during the last 20 trading days with a mark-up of 5%. The investors who signed up for the directed new share issue have undertaken not to sell the newly issued shares within 6 months from the Board’s decision, so-called Lock-up. The rights issue is carried out with the aim of securing further financing of the company’s working capital and the continued development of the company’s operations.